Roche has released its annual report for 2025 and presented new data on Alzheimer's disease. The company has also made several business and regulatory announcements, including a major agreement with Nurix Therapeutics and receiving priority review from the FDA for one of its treatments. Additionally, Roche has entered into a merger agreement to acquire PathAI and received regulatory approvals for various diagnostic tests.